Lipoprotein (a)[Lp (a)] has attracted the interest of researchers and physicians due to its
intriguing properties, including an intragenic multiallelic copy number variation in the LPA …

The high degree of size heterogeneity of apo (a), the distinct protein component of
lipoprotein (a)[Lp (a)], renders the development and selection of specific antibodies directed …

Importance Epidemiological and genetic data have implicated lipoprotein (a) as a potentially
modifiable risk factor for atherosclerotic disease and aortic stenosis, but there are no …

Abstract Lipoprotein (a)[Lp (a)] is a well-recognized, independent risk factor for
atherosclerotic cardiovascular disease, with elevated levels estimated to be prevalent in …

The aim of this updated statement is to provide comprehensive and timely evidence-based
recommendations on the prevention of stroke among individuals who have not previously …

Background: Lipoprotein (a)[Lp (a)] levels predict the risk of myocardial infarction (MI) in
populations of European ancestry; however, few data are available for other ethnic groups …

Risk for atherosclerotic cardiovascular disease (ASCVD) shows considerable heterogeneity
both in generally healthy persons and in those with known ASCVD. The foundation of …

Objective The development of these guidelines is mandated by the American Association of
Clinical Endocrinologists (AACE) Board of Directors and American College of Endocrinology …

Aims The aims of the study were, first, to critically evaluate lipoprotein (a)[Lp (a)] as a
cardiovascular risk factor and, second, to advise on screening for elevated plasma Lp (a), on …

Background and Purpose—This guideline provides an overview of the evidence on
established and emerging risk factors for stroke to provide evidence-based …